Israel's Ministry of Health has granted an approval to Brainsway to conduct a trial to test the efficacy of Deep Transcranial Magnetic Stimulation (TMS) system in treating autism in children with low functionality levels.
Brainsway TMS system is a noninvasive device which is designed to treat major depression, bipolar disorder and negative symptoms and cognitive impairment in schizophrenic patients.
The company said the trial, which will begin in the near future, will be conducted at Hadassah Medical Center Ein Kerem in Jerusalem, Israel and will include 40 patients.
Brainsway chief executive officer Uzi Sofer said, "While Brainsway has previously received approval for carrying out a study of our Deep TMS system together with Harvard Medical School in the United States on children with epilepsy, this will be our first clinical trial in a pediatric population in Israel."
